Rapidly progressive dementia - Insights
Mayo Clinic Laboratories’ first-in-class testing for rapidly progressive dementia and Creutzfeldt-Jakob disease uses a sensitive and specific seed amplification assay that detects and identifies prion proteins in CSF alongside a clinically...
Biopharma only testing - Insights
Find out how our suite of BioPharma Diagnostics-specific neurology testing can provide answers for your patients.
Learn how Mayo Clinic Laboratories testing for adrenal diseases can help physicians detect and classify adrenal disorders.
Learn more about how Mayo Clinic Laboratories helps hospital laboratories reduce costs and grow revenue.
Inborn errors of metabolism - Insights
Learn more about how Mayo Clinic Laboratories’ comprehensive menu of biochemical and molecular testing can diagnose inborn errors of metabolism.
At BioPharma Diagnostics, we are inspired by Mayo Clinic’s history of collaboration and breaking down barriers to change medicine. That’s why we bring Mayo Clinic expertise and quality to each project — from consulting through discovery to...
New tests launched in January - Insights
In January 2022, Mayo Clinic Laboratories announced twenty five new tests along with numerous reference value changes, obsolete tests, and algorithm changes.
Monoclonal Gammopathy Informative Cases - Insights
Mayo Clinic Laboratories provides evaluation and consultation for the diagnosis and treatment of patients with hereditary and acquired hematologic disorders.
Demyelinating neuropathies - Insights
Learn how our expert-backed testing can increase confidence when it comes to the identification of several demyelinating neuropathies.
Demyelinating disease - Insights
Learn about our demyelinating disease testing, including multiple sclerosis, AQP4/MOG-associated disorders, and spinal cord disorders.